884.00
+1.84%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orchid Pharma
Its shares trade on NSE under the ticker ORCHPHARMA.NS. It has been listed since 6 September 1993. In the fiscal year to 31 March 2026, it reported revenue of ₹8.11bn and net income of ₹205.5m. At that date it held total assets of ₹19.11bn and shareholders' equity of ₹12.88bn.
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). The company operates through the pharmaceutical segment. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Sept 1993
- Employees
- 838
- Website
- orchidpharma.com ↗
Leadership
Pay as last reported
- Shri. Ram AgarwalNon-Executive Non-Independent Chairman of the Board₹50,000
- Shri. Sunil GuptaChief Financial Officer
- Mr. Kapil DayyaCompliance Officer, Company Secretary
- Dr. R. SarangdharVice President, Unit Head - API and FDF
- Shri. Manish DhanukaManaging Director, Executive Director, since 2020₹7.3m
- Shri. Mridul DhanukaWhole Time Director, since 2020₹7.3m
- Dr. Srinivasan SHead - CTD and IPM
- Shri. Manoj GoyalNon-Executive Independent Director₹225,000
- Ms. Shubha SinghAdditional Non-Executive Independent Director
- Smt. Tanu SinglaNon-Executive Independent Director₹220,000
- Dr. Dharam VirNon-Executive Independent Director₹195,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orchid Pharma Ltd. manufactures Cephalosporins-Orals and Cephalosporins-Injectables APIs in Chennai, India.
- The company operates in anti-infectives and cardiovascular segments with 838 employees in Chennai.
- Orchid Pharma offers Cefixime Capsules and Acarbose Tablets across multiple therapeutic segments.
Weaknesses
- Orchid Pharma Ltd. has subsidiaries in Europe and the US but lacks a strong presence in Asia-Pacific markets.
- The company's focus on APIs may limit its growth in finished dosage forms compared to competitors.
- Orchid Pharma's product portfolio includes only a few nutraceuticals despite market demand.
Opportunities
- Expanding into anti-inflammatory and CNS segments could leverage Orchid Pharma's existing API capabilities.
- Growing demand for Cefoperazone and Sulbactam for Injection in global markets presents an opportunity.
- Orchid Europe Limited can help expand Orchid Pharma's presence in European healthcare markets.
Threats
- Competition from Indian pharmaceutical companies in the anti-infectives segment threatens Orchid Pharma's market share.
- Regulatory changes in the EU could impact Orchid Europe Limited's operations in Europe.
- Rising costs of raw materials may affect Orchid Pharma's API manufacturing profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.